916210-03-2 Usage
Uses
Used in Pharmaceutical Synthesis:
2-(trifluoromethyl)pyrimidine-4-carbonitrile is used as a building block in the pharmaceutical industry for the synthesis of various drugs. Its unique structure and reactivity allow for the creation of novel compounds with potential therapeutic applications.
Used in Agrochemical Synthesis:
In the agrochemical industry, 2-(trifluoromethyl)pyrimidine-4-carbonitrile serves as a key intermediate in the development of new pesticides and other agrochemical products. Its incorporation can enhance the effectiveness and selectivity of these compounds in agricultural applications.
Used in Material Science:
2-(trifluoromethyl)pyrimidine-4-carbonitrile may find applications in material science due to its potential to form new materials with unique properties. Its incorporation into polymers or other materials could lead to advancements in areas such as electronics, coatings, or advanced materials research.
Used in Chemical Research:
As a versatile compound, 2-(trifluoromethyl)pyrimidine-4-carbonitrile is utilized in chemical research to explore new reactions, mechanisms, and the development of innovative synthetic methods. Its reactivity and structural features make it a valuable tool for understanding and advancing the field of organic chemistry.
Check Digit Verification of cas no
The CAS Registry Mumber 916210-03-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,1,6,2,1 and 0 respectively; the second part has 2 digits, 0 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 916210-03:
(8*9)+(7*1)+(6*6)+(5*2)+(4*1)+(3*0)+(2*0)+(1*3)=132
132 % 10 = 2
So 916210-03-2 is a valid CAS Registry Number.
916210-03-2Relevant academic research and scientific papers
KCNT1 INHIBITORS AND METHODS OF USE
-
, (2020/11/23)
The present invention is directed to, in part, compounds and compositions useful for preventing and/or treating a neurological disease or disorder, a disease or condition relating to excessive neuronal excitability, and/or a gain-of-function mutation in a gene (e.g., KCNT1). Methods of treating a neurological disease or disorder, a disease or condition relating to excessive neuronal excitability, and/or a gain-of-function mutation in a gene such as KCNT1 are also provided herein.
HETEROBICYCLIC METALLOPROTEASE INHIBITORS
-
Page/Page column 160-161, (2008/06/13)
The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP- 13 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP- 13 inhibitors.
